New drug combo aims to save kidneys in pelvic cancer patients
NCT ID NCT07233252
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether a combination of tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy drug) can treat renal pelvic cancer while allowing patients to keep their kidney. About 35 adults with early-stage cancer will receive the drugs, and if the tumor shrinks enough, they may also get laser or freezing treatment to remove any remaining cancer. The main goal is to see if patients can avoid kidney removal for at least one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab and nab-paclitaxel
What this could lead to
If successful, this could offer a way to treat renal pelvic cancer without removing the kidney, preserving kidney function.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply widely. The combination therapy may cause side effects, and not all patients will respond well.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TISLELIZUMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Hospital of Tianjin Medical University
RECRUITINGTianjin, Outside U.S., 300211, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••